Impacts of endogenous retroviruses on tumorigenesis, immunity, stem cells, and research safety

Iyoko Katoh*
Molecular Biology, Center for Medical Education and Sciences, University of Yamanashi, Yamanashi, Japan
*Correspondence: iyoko@yamanashi.ac.jp
Edited by:
Paolo Pinton, University of Ferrara, Italy
Reviewed by:
Deilson Elgui De Oliveira, UNESP, Brazil
Keywords: human endogenous retrovirus, long terminal repeat, retrotransposon, endogenous retrovirus, carcinogenesis, stem cells

The human genome contains a category of repeat sequences referred to as human endogenous retroviruses (HERVs), which occupies up to 8% of the nucleotide sequences. HERVs have mutated and/or fragmented provirus structures of once-infectious retroviruses, and have lost their ability to replicate or transpose. Nonetheless, proteins encoded by different types of HERVs still show biological activities in various modes, and most of the regulatory regions termed “long terminal repeats” (LTRs) preserve the function as a promoter–enhancer region. Release from epigenetic silencing and activation of transcription factors can cause “awakening” of HERVs and LTRs involved in tumorigenesis, self-defense, and tissue development. This research topic is a compilation of unique reviews on HERVs and mouse endogenous retroviruses (ERVs) and original articles indicating new insights into HERVs.

HERV-K(HML-2) AS A FOSSIL VIRUS AND A FUNCTIONAL ELEMENT
Human endogenous retroviruses-K(HML-2), the most recently integrated HERV family, preserve a nearly complete retrovirus structure, and has been an interesting subject in virology, genome biology, oncology, and pathology of autoimmune diseases. In the comprehensive Review Article (1), Hohn et al. outlined current knowledge on HERV-K(HML-2) including the topics of endogeneration, genes-and-proteins, evolution, and tissue development. Moreover, the activation of HERV-K(HML-2) in diseases and the possibility of HERV-K-mediated oncogenesis were extensively discussed.

EXPRESSION OF HERV-K IN CANCERS
Agoni et al. contributed an Original Research Article (2) on the locus-specific analysis of HERV-K(HML-2) expression in prostate cancer cell lines. In addition to the previously known cancer types, melanoma, breast cancer, etc., prostate cancer was also found to express HERV-K and the LTR. Activation of specific HERV-K loci and an abundance of solo LTR-containing transcripts were described. As these authors mentioned, with deeper examination, this approach could possibly lead to determination of a clinical significance of HERV expression.

HERV AS THE TARGET OF CANCER IMMUNOTHERAPY
Tumor cells express extra genes, such as HERVs, that are repressed in normal cells. If a HERV-derived protein is tumor-specific, it could be a useful marker in cancer diagnosis and therapy. As described by Cherkasova et al. (3), this hypothesis was proven by identification of the novel HERV-E-derived peptides of renal cell carcinomas as the target antigens in successful hematopoietic stem cell transplantation therapy. The authors discussed the mechanism of cancer-specific HERV expression as well as immunological responses to various types of HERV proteins.

GREAT CONFUSION CAUSED BY A RECOMBINANT MOUSE ERV IN CANCER RESEARCH
In contrast to HERVs, ERVs of mouse laboratory strains currently remain active. Mice producing infectious viruses have provided interesting animal models for tumor biology in the past. Ironically, the nature of mouse ERVs has been recently “rediscovered” in human prostate cancer cells through contamination of a recombinant ERV termed xenotropic murine leukemia virus-related virus (XMRV). The Mini Review by Hempel et al. (4) covered the entire story, and raised alerts of the threat of XMRV-like virus spreading in laboratories, and for the virus-caused phenotypic changes of xenotransplanted cancer cells.

EPIGENETIC CHANGES OF RETROELEMENTS IN CANCERS
DNA hypomethylation is thought to be a major and common cause of the activation of retrotransposons in cancer development. Kreimer et al. (5) studied methylation status and expression of three retroelements, LINE-1, HERV-K, and AluY, in bladder cancer tissues and cell lines. They detected a considerable correlation between hypomethylation and transcription of LINE-1. Retroelements may undergo epigenetic control in different modes based on the tissues, subclasses, and chromosomal loci.

HERVs AS NON-MOVABLE TRANSPOSONS ASSOCIATED WITH HUMAN DISEASES
Human endogenous retroviruses and HERV-derived LTRs, with mammalian apparent LTR-retrotransposons (MaLRs), compose the subclass of LTR-retrotransposons. Recent evidence indicated association of these elements with pathogenesis and a beneficial
role in tumor therapy. Katoh and Kurata (6) summarized the influences of LTR-retrotransposons on human health and diseases, compared with presently active non-LTR-retrotransposons.

**IMMUNE REGULATION BY Mtv, THE ENDOGENOUS FORM OF MOUSE MAMMARY TUMOR VIRUS**

Mouse mammary tumor virus and Mtv have attracted HERV scientists because of the structural and functional similarity between MMTV/Mtv and certain HERVs, and the presence of superantigen (Sag) in MMTV/Mtv and HERV-K18. Holt et al. (7) contributed a fresh Review focusing on Mtv, in which the impacts of this element on immune responses, infectious diseases, and tumor development were discussed in great detail.

**MOUSE ENDOGENOUS RETROVIRUS MuERV-L/MERVL IN STEM CELLS**

Studies on epigenetic regulation of ERVs in mouse stem cells are, although indirectly, meaningful for elucidation of the status of HERVs in development and carcinogenesis. Schoorlemmer et al. (8) explained silencing of MERVL, a distinct type of ERV expressed at the two-cell stage after fertilization, by histone modification with orchestration of multiple proteins. They offered an interesting hypothesis of MERVL LTR-mediated regulation of neighboring genes relevant to the stem cell potency.

All these articles which came from diverse backgrounds illustrated HERVs/ERVs from the basics to the frontlines, providing new perspectives. There was a great deal of discussion concerning the epigenetic control of HERVs/ERVs in embryonic development and tumorigenesis. HERVs and LTRs are emerging as genome inhabitants associated with human pathogenesis.

**ACKNOWLEDGMENTS**

I dedicate this article to Yoji Ikawa.

**REFERENCES**

1. Hohn O, Hanke K, Bannert N. HERV-K(HML-2), the best preserved family of HERVs: endogenization, expression, and implications in health and disease. *Front Oncol* (2013) 3:246. doi:10.3389/fonc.2013.00246
2. Agoni L, Guha C, Lenz J. Detection of human endogenous retrovirus K (HERV-K) transcripts in human prostate cancer cell lines. *Front Oncol* (2013) 3:180. doi:10.3389/fonc.2013.00180
3. Cherkasova E, Weissman Q, Chids RW. Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors. *Front Oncol* (2013) 3:243. doi:10.3389/fonc.2013.00243
4. Hempel HA, Burns KH, De Marzo AM, Sfondes KS. Infection of xenotransplanted human cell lines by murine retroviruses: a lesson brought back to light by XMRV. *Front Oncol* (2015) 5:156. doi:10.3389/fonc.2013.00156
5. Kreimer U, Schulz WA, Koch A, Niegisch G, Goering W. HERV-K and LINE-1 DNA methylation and reexpression in urothelial carcinoma. *Front Oncol* (2013) 3:255. doi:10.3389/fonc.2013.00255
6. Katoh I, Kurata SI. Association of endogenous retroviruses and long terminal repeats with human disorders. *Front Oncol* (2013) 3:234. doi:10.3389/fonc.2013.00234
7. Holt MP, Shevach EM, Punksody GA. Endogenous mouse mammary tumor viruses: new roles for an old virus in cancer, infection, and immunity. *Front Oncol* (2013) 3:287. doi:10.3389/fonc.2013.00287
8. Schoorlemmer J, Perez-Palacios R, Climent M, Guallar D, Muniesa P. Regulation of mouse retroelement MuERV-L/MERVL expression by REX1 and epigenetic control of stem cell potency. *Front Oncol* (2014) 4:14. doi:10.3389/fonc.2014.00014

Received: 27 February 2014; accepted: 19 March 2014; published online: 31 March 2014.

Citation: Katoh I (2014) Impacts of endogenous retroviruses on tumorigenesis, immunity, stem cells, and research safety. *Front. Oncol.* 4:66. doi: 10.3389/fonc.2014.00066

This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology.

Copyright © 2014 Katoh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.